Chargement en cours...
RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes
Developing a novel therapeutic product for the treatment of type 2 diabetes (T2D) is a long, resource‐intensive process. Novel biomarkers could potentially aid clinical trial design by shortening clinical trials or enabling better prediction of at‐risk populations and/or disease progression. Novel c...
Enregistré dans:
| Publié dans: | Endocrinol Diabetes Metab |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8029523/ https://ncbi.nlm.nih.gov/pubmed/33855210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/edm2.207 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|